TokenPost·

Health Canada Approves Lilly’s Mounjaro for Cardiovascular Risk Reduction

Your call?

The indication applies to adults with type 2 diabetes and established cardiovascular disease, with the decision based on SURPASS-CVOT trial results.

Share

More news